![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, May 21, 2014 3:47:27 PM
- 30 months of funding
- 1 year away from trials
- 40 employees at ximedica working on this product
- 20 + medical experts say the video is better than state of art
- John currently talking about partnerships/sales in Europe
- CFO - $650k monthly burn rate
- CFO - Upto $80MM in Warrant funding to fund sales and post commercialization.
My opinions:
1) 50 million warrants though could dilute and not cause PPS appreciation like we expect
2) Mgmt is now less focused on PPS and more focused on product (I'm okay with this)
3) No Reverse Split (they didn't know what it was or why they would do it) - also no thinking currently of Nasdaq uplift.
Overall I would call this a Hold/Buy, as in, hold and buy more on dips. I can see this being a $800MM dollar company next year at the same time, and with say 120mm shares outstanding, that's about $6-$7 per share.
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM